Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases

Journal of the American College of Surgeons

Volumn 206, Issue 1, 2008, Pages 96-106

  Reddy, Srinevas K ^a   Morse, Michael A ^a   Hurwitz, Herbert I ^a   Bendell, Johanna C ^a   Gan, Tong J ^a   Hill, Steven E ^a   Clary, Bryan M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DISEASE SEVERITY; DOSE RESPONSE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; LIVER CANCER; LIVER RESECTION; MALE; MORBIDITY; OUTCOMES RESEARCH; PARTIAL HEPATECTOMY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORBIDITY; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; PRODRUGS; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37249002806     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.06.290     Document Type: Article

References (41)

1. Ferrera N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
2. Ellis L.M. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 33 (2006) S1-S7
3. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843-850
4. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350 (2004) 2335-2342
5. Hochester H.S. Bevacizumab in combination with chemotherapy: first-line treatment for patients with metastatic colorectal cancer. Semin Oncol 33 (2006) S8-S14
6. Hochester H.S., Hart L.L., Ramanathan R.K., et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-study. J Clin Oncol 24 (2006) 148s (abstr 3510)
7. Engstrom P.F., and Benson A.B. National Comprehensive Cancer Network clinical practice guidelines in oncology: colon cancer. Version 1.2007. http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf Accessed April 2, 2007
8. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
9. Hedrick E., Kozloff M., Hainsworth J., et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BriTE). J Clin Oncol 24 (2006) 155s (abstr 3536)
10. Van Cutsem E, Michael M, Berry S, et al. Preliminary safety and efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and capecitabine for mCRC: First BEATrial. Poster presented at the 2007 Gastrointestinal Cancers Symposium of the American Society of Surgical Oncology (abstr 346).
11. Kretzschmar A, Cunningham D, Berry S, et al. Feasibility of metastatectomy in patients treated with first-line bevacizumab for mCRC: preliminary results from the first BEAT study. Poster presented at the 2007 Gastrointestinal Cancers Symposium of the American Society of Surgical Oncology (abstr 343).
12. Giantonio B.J., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23 (2005) 1s (abstr 2)
13. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
14. Giantonio B.J., Levy D.E., O'Dwyer P.J., et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 17 (2006) 1399-1403
15. LeCouter J., Moritz D.R., Li B., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299 (2003) 890-893
16. Davidson A.J., and Zion L.I. Love, honor, and protect your liver. Science 299 (2003) 835-837
17. Marino G., Piazzese E., Gruttadauria S., et al. New model of liver regeneration induced through use of vascular endothelial growth factor. Transplantation Proc 38 (2006) 1193-1194
18. Bockhorn M., Goralski M., Prokofiev D., et al. VEGF is important for early liver regeneration after partial hepatectomy. J Surg Res 138 (2007) 291-299
19. Ollie E.W., Ren X., McClintock S.D., et al. Matrix metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice. Hepatology 44 (2006) 540-549
20. Taniguchi E., Sakisaka S., Matsuo K., et al. Expression of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 49 (2001) 121-129
21. Shimizu H., Miyazaki M., Wakabayashi Y., et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol 34 (2001) 683-689
22. Sturm J., Keese M., Zhang H., et al. Liver regeneration in FGF-2-deficient mice: VEGF acts as a potential substitute for FGF2. Liver Int 24 (2004) 161-168
23. Qiao J.G., Wu L., Lei D.X., and Wang L. Insulin promotes sinusoidal endothelial cell proliferation mediated by upregulation of vascular endothelial growth factor in regenerating rat liver after partial hepatectomy. World J Gastroenterol 11 (2005) 5978-5983
24. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006) 2065-2072
25. Fernandez F.G., Ritter J., Goodwin J.W., et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on respectability of hepatic colorectal metastases. J Am Coll Surg 200 (2005) 845-853
26. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after pre-operative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24 (2006) 4983-4990
27. Karoui M., Penna C., Amin-Hashem M., et al. Influence of chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243 (2006) 1-7
28. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466
29. Parikh A.A., Gentner B., WU T.T., et al. Perioperative complications in patient undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 7 (2003) 1082-1088
30. Zorzi D., Laurent A., Pawlik T.M., et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94 (2007) 274-286
31. Strasberg S.M. Terminology of liver anatomy and liver resections: coming to grips with hepatic Babel. J Am Coll Surg 184 (1997) 413-434
32. Mullen J.T., Ribero D., Reddy S.K., et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 204 (2007) 854-864
33. Dindo D., Demartines N., and Clavien P.A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240 (2004) 205-213
34. Namisaki T., Yoshiji H., Kojima H., et al. Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats. J Hepatol 44 (2006) 568-575
35. Redaelli C.A., Samela D., Carrick F.E., et al. Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol 40 (2004) 305-312
36. Skillings J.R., Johnson D.H., Miller K., et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 23 (2005) 196s (abstr 3019)
37. Hurwitz H., and Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 33 (2006) S26-S34
38. Kesmodel S.B., Ellis L.M., Lin E., et al. Pre-operative bevacizumab does not increase post-operative complications in patients undergoing hepatic surgery for colorectal cancer liver metastases. Ann Surg Oncol 14 (2007) 17-18 (abstract 52)
39. D'Angelica M., Kornprat P., Gonen M., et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14 (2007) 759-765
40. Gruenberger T., Gruenberger B., and Scheithauer W. Neoadjuvant therapy with bevacizumab. J Clin Oncol 24 (2006) 2592-2593
41. Ellis L.M., Curley S.A., and Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23 (2005) 4853-4855